Continuing cetuximab after first treatment stops working for metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if continuing the targeted therapy cetuximab after initial treatment stops working can help people with advanced colorectal cancer. Participants have a specific gene profile (RAS and BRAF normal) and their cancer responds well at first.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic colorectal cancer (cancer that has spread).
- Your first treatment included cetuximab or a similar drug, and it worked well for at least 6 months or shrunk tumors significantly.
- That treatment has now stopped working (cancer has progressed).
- You have a specific genetic type: RAS and BRAF genes are normal (wild-type).
- You are healthy enough for daily activities (ECOG score 0 or 1).
- You are 18 years or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new approach for people with a specific type of metastatic colorectal cancer that has stopped responding to initial treatments. It compares reusing a targeted drug combination (irinotecan plus cetuximab) versus a different chemotherapy plus a targeted drug (trifluridine/tipiracil plus bevacizumab) to see which works better for patients whose tumors have a certain genetic profile.
This trial tests a combination of two drugs—cetuximab or bevacizumab plus a chemotherapy pill (trifluridine/tipiracil)—for people with metastatic colorectal cancer that has no RAS or BRAF mutations. It's for patients whose cancer grew after first responding to cetuximab, and who have had other treatments since then.
This trial compares giving the targeted drug cetuximab continuously vs. intermittently, alongside standard chemotherapy, for people with advanced colorectal cancer whose tumors are RAS/BRAF wild-type. It aims to see if taking breaks from cetuximab works just as well while reducing side effects.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two targeted drugs (cetuximab beta and fruquintinib) with or without an immunotherapy drug for people with a specific type of advanced colorectal cancer that has not been treated before. It aims to see if this approach is safe and effective for those whose tumors have certain genetic markers (RAS and BRAF wild type).
This study compares two different combinations of chemotherapy plus a targeted therapy called cetuximab as a first treatment for a specific type of advanced colorectal cancer. The goal is to see which combination works better and has fewer side effects.
Hear when a new Metastatic Colorectal Cancer (mCRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.